Drugs / EG-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07281105 | Aug 2018 → Aug 2025 | central nervous system lupus, cognitive impairment with or without cerebellar ataxia | Evergreen Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07281105 ↗ |
| Action | Inhibit | “low-affinity NMDA receptor antagonist” NCT07281105 ↗ |
| Route | Oral | “EG-501/ EG-MNTP-01 is an oral, low-affinity NMDA receptor antagonist.” NCT07281105 ↗ |